SCHEMBL3570478

SCHEMBL3570478

O=C(/C=C/c1cccc2c1OCO2)/C=C/c1cccc2c1OCO2

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.60
KDM4E B2RXH2 2/20 0.59
GSK3B P49841 1/20 0.47
NFE2L2 Q16236 3/20 0.46
NFKB1 P19838 2/20 0.46
JUN P05412 1/20 0.46
HSD11B1 P28845 1/20 0.44
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
TFEB P19484 1/20 0.41
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.39
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
KDM4C Q9H3R0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3570479 1.00 MAOB (0.60) MAOBKDM4EGSK3BNFE2L2NFKB1
SCHEMBL162076 0.88 KDM4E (0.77) MAOBKDM4EGSK3BNFKB1DRD2
SCHEMBL162075 0.88 KDM4E (0.77) MAOBKDM4EGSK3BNFKB1DRD2
SCHEMBL5478845 0.87 MAOB (0.61) MAOBKDM4EGSK3BDRD2DRD3
SCHEMBL5478840 0.87 MAOB (0.61) MAOBKDM4EGSK3BDRD2DRD3
SCHEMBL8489579 0.84 KDM4E (0.70) MAOBKDM4EGSK3BNFKB1DRD2
SCHEMBL8489573 0.84 KDM4E (0.70) MAOBKDM4EGSK3BNFKB1DRD2
SCHEMBL10973706 0.81 MAOB (0.55) MAOBKDM4EGSK3BDRD2DRD3
SCHEMBL6678057 0.81 MAOB (0.55) MAOBKDM4EGSK3BDRD2DRD3
SCHEMBL20490106 0.81 MAOB (0.52) MAOBKDM4EGSK3BDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842705-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2010-11-30 US disclosed
US-7842705-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2010-11-30 US disclosed
US-7842705-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2010-11-30 US disclosed
WO-2008150899-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER AND INFLAMMATORY DISEASES EMORY UNIVERSITY (US) 2008-12-11 WO disclosed
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES EMORY UNIVERSITY 2008-09-25 US disclosed
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES EMORY UNIVERSITY 2008-09-25 US disclosed
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES EMORY UNIVERSITY 2008-09-25 US disclosed
US-7371766-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2008-05-13 US disclosed
US-7371766-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2008-05-13 US disclosed
US-7371766-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2008-05-13 US disclosed
US-20040176384-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY 2004-09-09 US disclosed
US-6664272-B2 Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue EMORY UNIVERSITY 2003-12-16 US disclosed
EP-1242379-A1 CURCUMIN ANALOGUES FOR TREATING CANCER Emory University (US) 2002-09-25 EP disclosed
WO-2001040188-A9 CURCUMIN ANALOGUES FOR TREATING CANCER UNIV EMORY (US) 2002-07-25 WO disclosed
US-20020019382-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY 2002-02-14 US disclosed
WO-2001040188-A1 CURCUMIN ANALOGUES FOR TREATING CANCER EMORY UNIVERSITY (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176384-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties PGF, VEGFA, VHL MAOB 3388/4885KDM4E 1558/4885GSK3B 4175/4885
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES PGF, VEGFA, VHL MAOB 3388/4885KDM4E 1558/4885GSK3B 4175/4885
US-20020019382-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties PGF, VEGFA, VHL MAOB 3388/4885KDM4E 1558/4885GSK3B 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.